Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central nervous system disorders, faced a setback at the Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin, a drug intended to treat hallucinations and delusions associated with Alzheimer’s disease psychosis. The...
Geron Corporation, Inc. (NASDAQ: GERN) is a late-stage clinical biotechnology company developing a first-in-class telomerase inhibitor, imetelstat, intended to treat hematologic malignancies. The Company’s lead candidate Imetelstat is a novel first-in-class telomerase inhibitor currently undergoing a Phase 3 trial, IMerge, which is a double-blind, randomized,...
BeyondSpring, Inc. (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on creating transformative treatments for immune-oncology conditions. The Company’s lead candidate is plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), which possess a unique mechanism of action and was evaluated in Phase 3 clinical trials in...
Heron Therapeutics, Inc. (NASDAQ: HRTX) has a major upcoming catalyst in the form of the upcoming Prescription Drug User Fee Act (PDUFA) date for FDA approval on May 12, 2021 for HDX-011 (Zynrelef). HTX-011 is an extended-release, dual-acting local anesthetic that uses a combination of...
